SETANAXIB
( DrugBank: Setanaxib / KEGG DRUG: - )
1 disease
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
93 | Primary biliary cholangitis | 9 |
93. Primary biliary cholangitis
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
Showing 1 to 9 of 9 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2021-001810-13-SE (EUCTR) | 06/04/202220220406 | 30/11/202120211130 | A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFORM) A Trial of Setanaxibin Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFOR ... | TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness - TRANSFORM TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Set ... | Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primary biliary cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classi ... | Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: GYPP-06 (GKT137831 free base), C10071301-D Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: ... | Calliditas Therapeutics Suisse SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 318 | Phase 2;Phase 3 | United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;France;Hungary;Canada;Belgium;Poland;Denmark;Australia;Germany;New Zealand;Sweden United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;France;Hungary;Ca ... | ||
2 | NCT05014672 (ClinicalTrials.gov) | February 14, 202220220214 | 10/8/202120210810 | A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness | TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib With a 52-week Extension Phase in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Set ... | Primary Biliary Cholangitis;Liver Stiffness | Drug: Setanaxib;Drug: Placebo | Calliditas Therapeutics Suisse SA | NULL | Recruiting | 18 Years | N/A | All | 318 | Phase 2/Phase 3 | United States;Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom United States;Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Ne ... |
3 | EUCTR2021-001810-13-DE (EUCTR) | 10/02/202220220210 | 07/10/202120211007 | A Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with PBC and Elevated Liver Stiffness A Phase 2b/3 Trial of Setanaxibwith a 52 week Extension Phase in Patients with PBC and Elevated Live ... | TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness - TRANSFORM TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Set ... | Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primary biliary cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classi ... | Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: GYPP-06 (GKT137831 free base), C10071301-D Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: ... | Genkyotex Suisse SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 318 | Phase 2;Phase 3 | United States;Czechia;Greece;Spain;Austria;Israel;Switzerland;United Kingdom;Italy;France;Hungary;Canada;Poland;Belgium;Australia;Denmark;Netherlands;Germany;New Zealand;Sweden United States;Czechia;Greece;Spain;Austria;Israel;Switzerland;United Kingdom;Italy;France;Hungary;Ca ... | ||
4 | EUCTR2021-001810-13-IT (EUCTR) | 18/01/202220220118 | 05/11/202120211105 | A Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with PBC and Elevated Liver Stiffness A Phase 2b/3 Trial of Setanaxibwith a 52 week Extension Phase in Patients with PBC and Elevated Live ... | TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness - TRANSFORM TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Set ... | Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primary biliary cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classi ... | Product Name: SETANAXIB Product Code: [GKT137831] INN or Proposed INN: Setanaxib | Genkyotex Suisse SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 318 | Phase 2;Phase 3 | United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Poland;Belgium;Australia;Denmark;Germany;Netherlands;New Zealand;Sweden United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Ca ... | ||
5 | EUCTR2021-001810-13-ES (EUCTR) | 17/01/202220220117 | 19/10/202120211019 | A Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with PBC and Elevated Liver Stiffness A Phase 2b/3 Trial of Setanaxibwith a 52 week Extension Phase in Patients with PBC and Elevated Live ... | TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness - TRANSFORM TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Set ... | Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primary biliary cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classi ... | Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: GYPP-06 (GKT137831 free base), C10071301-D Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: ... | Genkyotex Suisse SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 318 | Phase 2;Phase 3 | United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Poland;Belgium;Australia;Denmark;Netherlands;Germany;New Zealand;Sweden United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Ca ... | ||
6 | EUCTR2021-001810-13-AT (EUCTR) | 13/01/202220220113 | 11/10/202120211011 | A Trial of Setanaxib in Patients with Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFORM) A Trial of Setanaxibin Patients with Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFOR ... | TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness - TRANSFORM TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Set ... | Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primary biliary cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classi ... | Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: GYPP-06 (GKT137831 free base), C10071301-D Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: ... | Calliditas Therapeutics Suisse SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 318 | Phase 2;Phase 3 | United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;France;Hungary;Canada;Belgium;Poland;Denmark;Australia;Germany;New Zealand;Sweden United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;France;Hungary;Ca ... | ||
7 | EUCTR2021-001810-13-PL (EUCTR) | 11/01/202220220111 | 28/10/202120211028 | A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFORM) A Trial of Setanaxibin Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFOR ... | TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness - TRANSFORM TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Set ... | Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primary biliary cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classi ... | Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: GYPP-06 (GKT137831 free base), C10071301-D Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: ... | Calliditas Therapeutics Suisse SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 318 | Phase 2;Phase 3 | United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;France;Hungary;Canada;Belgium;Poland;Denmark;Australia;Germany;New Zealand;Sweden United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Italy;Switzerland;France;Hungary;Ca ... | ||
8 | EUCTR2021-001810-13-HU (EUCTR) | 11/12/202120211211 | 30/09/202120210930 | A Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with PBC and Elevated Liver Stiffness A Phase 2b/3 Trial of Setanaxibwith a 52 week Extension Phase in Patients with PBC and Elevated Live ... | TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness - TRANSFORM TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Set ... | Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primary biliary cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classi ... | Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: GYPP-06 (GKT137831 free base), C10071301-D Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: ... | Genkyotex Suisse SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 318 | Phase 2;Phase 3 | United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Poland;Belgium;Australia;Denmark;Germany;Netherlands;New Zealand;Sweden United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Ca ... | ||
9 | EUCTR2021-001810-13-GR (EUCTR) | 07/12/202120211207 | 12/11/202120211112 | A Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with PBC and Elevated Liver Stiffness A Phase 2b/3 Trial of Setanaxibwith a 52 week Extension Phase in Patients with PBC and Elevated Live ... | TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness - TRANSFORM TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Set ... | Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classification code 10080429;Term: Primary biliary cholangitis;System Organ Class: 10019805 - Hepatobiliary disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness MedDRA version: 21.0;Level: PT;Classi ... | Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: GYPP-06 (GKT137831 free base), C10071301-D Product Name: SETANAXIB Product Code: GKT137831 INN or Proposed INN: Setanaxib Other descriptive name: ... | Genkyotex Suisse SA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 318 | Phase 2;Phase 3 | United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Canada;Poland;Belgium;Australia;Denmark;Netherlands;Germany;New Zealand;Sweden United States;Czechia;Greece;Spain;Austria;Israel;United Kingdom;Switzerland;Italy;France;Hungary;Ca ... |